FINHUB Insights

REGN · Q3 FY25 · Jul 1 – Sep 30, 2025

Regeneron Pharmaceuticals Q3 FY25: where the revenue came from and where it went

Regeneron Pharmaceuticals Q3 FY25: revenue $3.8B (+1% year over year). Net profit $1.5B. Largest cohort Collaboration Revenue $2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 28, 2025 10-Q
Sankey diagram of Regeneron Pharmaceuticals's income statement for Q3 FY25: revenue of $3.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.8B +1% year over year
Gross profit$3.5B 93% margin
Operating profit$1B 27% margin
Net profit$1.5B 39% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.8 100% +1%
Collaboration Revenue 2 53% +19%
Product 1.6 42% −18%
Product and Service Other 0.2 5% +74%
Cost of revenue−0.38%
Gross profit3.593% margin+0pp
Research & development−1.439%+5pp
SG&A−0.718%−2pp
Other−0.38%+0pp
Operating profit127% margin−4pp
Tax−0.2
Net profit1.539%+3pp
Filing on EDGAR More quarters of REGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters